Moleculin Biotech, Inc. (NASDAQ:MBRX) tinted loss of 0% (0 points) to US$1.69. The volume of 0.19 Million shares climbed down over an trading activity of 281.93 Million shares. EPS ratio determined by looking at last 12 month figures is -0.56. Over the same time span, the stock marked US$3.4 as its best level and the lowest price reached was US$1.36. The corporation has a market cap of US$43.28 Million.
Moleculin Biotech, Inc. (NASDAQ:MBRX)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -60.3 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 9.8 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Vantage Energy Acquisition Corp. (NASDAQ:VEAC) is worth US$20.09 Million and has recently fallen 0% to US$9.9. The latest exchange of 0.05 Million shares is below its average trading activity of 29.91 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$9.97 while the mean 12-month price target for the shares is US$0.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 31.73, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 70.43%, it carries an earnings per share ratio of 0.